Why is Mangalam Drugs falling/rising?

As of 29-Jul, Mangalam Drugs and Organics Ltd is currently priced at 87.20, reflecting a decrease of 0.62, or 0.71%. The stock has been underperforming, having fallen consecutively for the last four days, resulting in a total decline of 5.99% during this period. In terms of returns, the stock has shown a negative performance of 4.92% over the past week and a significant decline of 24.80% year-to-date. Despite a notable increase in profits by 176.5% over the past year, the stock has generated a return of -22.07%, indicating weak long-term fundamental strength, particularly with a low Return on Equity of 7.99% and a high Debt to EBITDA ratio of 2.74 times. In the broader market context, the Sensex has declined by only 1.03% over the past week, suggesting that Mangalam Drugs is underperforming relative to the benchmark. The stock's recent performance is further compounded by a decrease in investor participation, with delivery volume falling by 34.67% against the five-day average. Although the stock is trading at a discount compared to its peers and has a very attractive valuation with a PEG ratio of 0.1, the consistent underperformance against the benchmark over the last three years raises concerns for investors.